A clinical trial to assess the safety and efficacy of an oral medication called Etrasimod for moderately active ulcerative colitis (UC).
About this study
The purpose of this study is to assess the efficacy and safety of Etrasimod in participants with moderately active ulcerative colitis (UC).
Etrasimod is designed to block the movement of some kind of cells in your body (part of your immune system called lymphocytes) to areas of inflammation in the colon.
Etrasimod is an experimental treatment. This means that it is not approved treatment for UC by Regulatory Authorities such as the Therapeutic Goods Administration (TGA) in Australia and the Food and Drug Administration (FDA) in the United States.
Anticipated enrolment close date: 31 December 2026
Contact the Clinical Trials Centre for more information.
Who can take part
- People who are aged 18 to 80 years of age and have a clinical diagnosis of UC
- You cannot participate if you have had a total or partial colectomy and/or if you have a diagnosis of Crohn's disease.
You will need to undergo or provide the following:
- Medical history
- Physical exam
- Electrocardiogram (ECG)
- Weight, height, blood pressure, pulse, heart rate
- Health questionnaires
- Blood samples
- Urine test
- Colonoscopy with biopsy collection
- Stool tests
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.
The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.
The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.